These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - Morgan Stanley (NYSE:MS) upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Equalweight to Overweight on Wednesday, while raising its price target to $62.00 from $55.00. The stock, currently trading at $43.37 with a market capitalization of $6.88 billion, has shown strong momentum with an 18.65% gain year-to-date. According to InvestingPro data, analyst targets for the stock range from $37 to $83.
The upgrade follows Ionis Pharmaceuticals’ second-quarter 2025 financial results, which exceeded analyst expectations and prompted the company to raise its guidance for the remainder of the year. InvestingPro analysis shows the company maintains strong financial flexibility with a current ratio of 9.66, indicating robust liquidity to support its growth initiatives.
Morgan Stanley cited strong early launch trends for Tryngolza, Ionis’ treatment for severe hypertriglyceridemia (SHTG), as a key factor in its decision to upgrade the stock.
The investment bank noted that recent key opinion leader feedback has increased its conviction in the market opportunity for Tryngolza in the SHTG space.
Morgan Stanley expects continued momentum for Ionis Pharmaceuticals, supported by multiple upcoming catalysts that could further drive the company’s performance.
In other recent news, Ionis Pharmaceuticals Inc. reported its second-quarter 2025 earnings, revealing a strong financial performance that exceeded expectations. The company achieved a revenue of $452 million, which was significantly higher than the forecasted $286 million, resulting in a 58.04% revenue surprise. Additionally, the earnings per share (EPS) reached $0.70, a notable improvement compared to the anticipated -$0.24. These results reflect a substantial financial turnaround for the company. The earnings report has been a focal point for analysts, with some firms likely to adjust their projections based on these figures. This development marks an important moment for Ionis Pharmaceuticals as it continues to navigate the competitive pharmaceutical landscape. Investors are closely monitoring these outcomes to gauge future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.